Abstract
Objective To explore the application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with tegafur, gimeracil, and oteracil potassium (TS-1) and its influence on quality of life (QOL). Methods Clinical data of 92 patients with advanced squamous cell carcinoma of the lung treated with erlotinib and TS-1 in our hospital (January 2017–January 2021) were retrospectively analyzed. Forty-six patients receiving conventional nursing were set as the control group (CG), and other 46 patients receiving evidence-based nursing intervention additionally were set as the study group (SG). The clinical observation indexes of the two groups were compared and analyzed. Results No obvious difference in general data between both groups (P > 0.05). According to EORTC QLQ-C30, compared with the CG, the scores of role function, physical function, social function, cognitive function, and emotional function in the SG were remarkably higher (P < 0.05). After intervention, scores of VAS of patients were obviously lower than those before intervention (P < 0.05), and scores of VAS in the SG after intervention were obviously lower than those in the CG (P < 0.05). After intervention, scores of SAS and SDS were lower than those before intervention, and those of the SG were obviously lower than those of the SG (P < 0.05). Compared with the CG, incidences of adverse reactions such as diarrhoea, nausea and vomiting, erythra, pressure sores, and leukopenia in the SG were obviously lower (P < 0.05). Compared with the CG, “very satisfied” and total satisfaction in the SG were obviously higher (P < 0.05). Conclusion Application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with TS-1 can help patients to relieve pain, improve their psychological state, reduce the incidence of adverse reactions, significantly improve the QOL, and also enhance the satisfaction of clinical nursing.
Highlights
Squamous cell carcinoma of the lung is one of the nonsmall cell lung cancers (NSCLC) and the most common type of lung cancer, with the incidence and the mortality ranking the first among lung cancers in China [1,2,3]
(2) According to TNM stages, patients were evaluated as the stage IV. (3) Patients were in line with the indications of the treatment by erlotinib combined with TS-1. (4) e expected survival period was more than 3 months
The sensitivity of the cancer to chemoradiotherapy is greatly reduced at the advanced stage, which results in poor treatment effect
Summary
Squamous cell carcinoma of the lung is one of the nonsmall cell lung cancers (NSCLC) and the most common type of lung cancer, with the incidence and the mortality ranking the first among lung cancers in China [1,2,3]. E combined chemotherapy is usually served as the conservative scheme in clinical application to relieve symptoms, enhance survival rate, and improve the quality of life (QOL) [4,5,6,7]. Erlotinib combined with TS-1 was implemented in our hospital for patients with advanced squamous cell carcinoma of the lung, which has achieved high disease control rate. Less clinical data are available in patients with advanced squamous cell carcinoma of the lung. This paper will explore the application of evidence-based intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib and TS-1 and its influence on QOL, so as to promote the QOL in such patients in the treatment of advanced disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
